N
Nanjing Jingjie Biotechnology
Precision point-of-care in-vitro diagnostic and monitoring devices
About Nanjing Jingjie Biotechnology
Nanjing Jingjie Biotechnology Co., Ltd., operating as Eaglenos Sciences, is a biotechnology company founded in 2018 that develops, manufactures, and markets diagnostic devices. The company is headquartered in Nanjing, China, and has expanded to establish a research and development base of over 7,500 square meters.
Eaglenos specializes in precise point-of-care testing (POCT) products for home and clinical settings, focusing on chronic diseases like diabetes and cardiovascular conditions. Its product lineup features three main platforms: cartridge testing, paper-strip testing, and dynamic monitoring. Key products include multi-functional monitoring meters for blood glucose, uric acid, lactate, and ketones, as well as blood gas and electrolyte analyzers for acute care settings like ICUs and emergency rooms. These devices are engineered using the company's core technologies in electrochemistry, microfluidics, and signal acquisition.
The company serves both individual users and medical institutions, offering digital data management platforms and integrated health solutions to complement its hardware. Eaglenos generates revenue through the production and sale of its diagnostic devices, wearable monitoring systems, and health management products. The company is privately held and venture capital-backed, having secured a Series A funding round of $22 million in February 2023.
Source: Dealroom company dataKnowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | May 2023 | $21M | $83M | Huatai Zijin Investment · Innomed Capital · Shanghai Changjiang Guohong Investment Management · 3E Bioventures | ↗ |
Growth signals
Latest recorded traffic for Nanjing Jingjie Biotechnology is 13K monthly website visits, up 622.2% over the last three months. Nanjing Jingjie Biotechnology's team grew 2300% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Huatai Zijin Investment- ICInnomed Capital
- SMShanghai Changjiang Guohong Investment Management
3E Bioventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Nanjing Jingjie Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Nanjing Jingjie Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.






